Product Images Aripiprazole

This is a description of the effects of certain drugs on aripiprazole's pharmacokinetics. The text lists several drugs such as ketoconazole, quinidine, carbamazepine, famotidine, valproate, and lorazepam, and describes their effect as either inhibitors or inducers of certain enzymes. The text also shows fold change and 90% confidence intervals for the concentrations of aripiprazole in the presence of these drugs, as well as changes relative to the reference without interacting drugs. Overall, this information could be useful for understanding potential drug interactions with aripiprazole.*

This is a table showing the effects of different drugs on the pharmacokinetics of dehydro-aripiprazole (a metabolite of aripiprazole). The table includes information on fold change and 90% confidence interval of dehydro-aripiprazole PK (pharmacokinetics) for each drug. The drugs evaluated are CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine) and other drugs (valproate and lorazepam).*

This is a table (Figure 3) that displays the effects of aripiprazole on the pharmacokinetics (AUC and Cmax) of other drugs. The drugs listed in the table include extropmethorphan, Swartarin, Revartarin, omeprazole, lamotrigine, valproate, lorazepam, yontane, and O-desmethyivenlafaxine. The table also provides the fold change and 90% confidence interval for the effects of aripiprazole on these drugs.*

This appears to be a tabular data on the PK AdpprzcleFad Change for different special populations such as Gender (female vs. male), Age (Wostsssyarsod AC), HopatcInpairment, and Renal impairment. The table is showing the relative change for each group compared to a Reference group and the percentage change is also included for some groups. However, the purpose and context of this information are not available.*

The text appears to be a figure caption in a scientific document, showing the effects of intrinsic factors on the pharmacokinetics of dehydro-aripiprazole. It includes information on gender, age, hepatic impairment, and renal impairment, and plots changes relative to a reference value. However, without the actual figure or more context, it is difficult to provide a more specific description.*

This is a graph (Figure 6) displaying the Kaplan-Meier Estimation of the cumulative proportion of patients with relapse in Schizophrenia Study 5. It compares the relapse rates of patients taking Aripiprazole versus those taking the placebo. The proportion of patients with relapse is represented on the y-axis while the x-axis represents the number of days from randomization. The number of subjects at risk is also shown for both Aripiprazole and the placebo.*

This is a label for Aripiprazole 5mg tablets that have been relabeled by Proficient Rx LP based in Thousand Oaks, CA. The tablets are blue-colored, modified rectangular shaped and uncoated, with '62 T ST' debossed on one side and 'H' on the other. The lot number and expiration date are provided. Each bottle contains 30 tablets with a medication guide to be provided to each patient separately. The manufacturer is Aurobindo Pharma Limited based in Hyderabad, India. Keep the medication out of reach of children.*